Cardiovascular diabetology

GLP-1 drugs and protection against heart and metabolism diseases: past progress and future challenges

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have expanded their therapeutic applications beyond glycemic control in type 2 diabetes and obesity.

  • GLP-1RAs are associated with cardiovascular, renal, and hepatic benefits.
  • Recent clinical trials highlight the diverse effects of GLP-1RAs on various cardiometabolic conditions.
  • The discovery of GLP-1 has been a key milestone in the evolution of treatments for these diseases.
  • Future challenges include understanding the mechanisms of cardiometabolic protection offered by GLP-1RAs.

Simplified

Key numbers

3 of 5
3 of 5
GLP-1RAs evaluated in major cardiovascular outcomes trials.
40 weeks
40 weeks
Duration of the SURPASS-2 trial evaluating tirzepatide.

Full Text

We can’t show the full text here under this license.
View Full Text ↗

Funding

Competing interests

Declarations. Competing interests: Enrique Fisman (EF), Editor-in-Chief, and Francisco Westermeier (FW), Deputy Editor of Cardiovascular Diabetology, are the authors of this editorial. Both authors declare no additional competing interests related to this work.
PubMed

Related papers

Dec '18
How GLP-1 receptor drugs for type 2 diabetes may affect the heart and blood vessels, with a summary of heart-related study results
top 2% journal
cited by 127 papers
research support, non-u.s. gov't
Jul '19
Glucagon-like peptide-1 drugs for treating type 2 diabetes in people with chronic kidney disease and their effects on the kidneys
top 20% journal
cited by 46 papers
journal article
Apr '25
How well newer GLP-1RA drugs work when added to SGLT2i treatment in type 2 diabetes
top 2% journal
cited by 25 papers
comparative study
Jan '20
How SGLT2 Inhibitors and GLP-1 Receptor Agonists May Lower Heart Disease Risk: Completed and Ongoing Mechanism Studies
top 5% journal
cited by 51 papers
journal article
Aug '24
Key health outcomes in type 2 diabetes linked to SGLT2 inhibitors and GLP-1 receptor agonists
cited by 4 papers
journal article
Nov '21
Tirzepatide, a new medicine that activates two blood sugar hormones, as a potential heart and metabolism treatment
top 2% journal
cited by 106 papers
journal article
Dec '20
Glucagon-like peptide-1 receptor agonists' effects on blood sugar control and body measurements in diabetic patients with fatty liver disease
top 20% journal
cited by 16 papers
systematic review
Nov '24
Updated evidence on heart and kidney effects of GLP-1 drugs alone and combined with SGLT2 inhibitors and finerenone
top 2% journal
cited by 36 papers
journal article
Jul '24
How the diabetes drug tirzepatide may affect heart health compared to similar treatments
top 2% journal
cited by 43 papers
research support, non-u.s. gov't

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 days ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
1 week ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
2 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
3 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
4 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
5 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
6 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
7 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
8 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief